Ken Griffin Olema Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$8.73 - $13.99 $133,569 - $214,047	15,300 Added 90.53%	32,200 $348,000
Q1 2024 May 15, 2024	SELL	$10.95 - $16.62 $141,255 - $214,398	-12,900 Reduced 43.29%	16,900 $191,000
Q4 2023 Feb 14, 2024	BUY	$10.53 - $17.14 $80,028 - $130,264	7,600 Added 34.23%	29,800 $418,000
Q3 2023 Nov 14, 2023	BUY	$8.19 - $12.98 $75,348 - $119,416	9,200 Added 70.77%	22,200 $274,000
Q2 2023 Aug 14, 2023	BUY	$3.22 - $9.65 $41,860 - $125,450	13,000 New	13,000 $117,000
Q4 2022 Feb 14, 2023	SELL	$2.27 - $3.76 $34,504 - $57,152	-15,200 Reduced 43.18%	20,000 $49,000
Q3 2022 Nov 14, 2022	SELL	$2.72 - $5.88 $34,272 - $74,088	-12,600 Reduced 26.36%	35,200 $97,000

129

57.8M

57.5K

34K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $479M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.